AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference
AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th , 2022 at 8:00 AM ET.
AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC4.7.2022 13:32:06 CEST | Press release
SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China
INVERTO4.7.2022 12:44:13 CEST | Pressemeddelelse
INVERTO: Forsyningssikkerhed til enhver pris
BEARINGPOINT4.7.2022 10:00:11 CEST | Press release
BearingPoint Appoints 19 New Partners Across Europe
VOOPOO4.7.2022 09:17:05 CEST | Press release
VOOPOO Unveils 3 New Products, Telling Story of Its 8-year Entrepreneurship Journey in 30 Minutes
JAB-HOLDING4.7.2022 09:02:08 CEST | Press release
AGILA Pet Insurance becomes part of JAB Backed Pinnacle Pet Group, to create a Leading Pan-European Pet Insurance Platform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom